BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M. Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy. J Clin Med 2019;9:E64. [PMID: 31888054 DOI: 10.3390/jcm9010064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 2017; 8(2): 120-134 [PMID: 28439493 DOI: 10.5306/wjco.v8.i2.120] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 88] [Article Influence: 25.5] [Reference Citation Analysis]
3 Sung NJ, Kim NH, Bae NY, Jo HS, Park SA. DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells. Biosci Rep 2020;40:BSR20200164. [PMID: 32141512 DOI: 10.1042/BSR20200164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kharabsheh HA, Scott JE. CoAsy knockdown in TNBC cell lines resulted in no overt effect on cell proliferation in vitro. Biochem Biophys Res Commun 2020;530:136-41. [PMID: 32828275 DOI: 10.1016/j.bbrc.2020.06.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Iqbal MA, Chattopadhyay S, Siddiqui FA, Ur Rehman A, Siddiqui S, Prakasam G, Khan A, Sultana S, Bamezai RN. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications. FEBS J 2021;288:471-85. [PMID: 32356386 DOI: 10.1111/febs.15353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Santos KF, Gutierres JM, Pillat MM, Rissi VB, Santos Araújo MD, Bertol G, Gonçalves PB, Schetinger MR, Morsch VM. Uncaria tomentosa extract alters the catabolism of adenine nucleotides and expression of ecto-5'-nucleotidase/CD73 and P2X7 and A1 receptors in the MDA-MB-231 cell line. J Ethnopharmacol 2016;194:108-16. [PMID: 27590731 DOI: 10.1016/j.jep.2016.08.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, Kesharwani SS. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release 2020;326:628-47. [PMID: 32653502 DOI: 10.1016/j.jconrel.2020.07.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
8 Guo CH, Hsia S, Chung CH, Lin YC, Shih MY, Chen PC, Peng CL, Henning SM, Hsu GW, Li Z. Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer. J Nutr Biochem 2021;87:108504. [PMID: 32956826 DOI: 10.1016/j.jnutbio.2020.108504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Anwar MM, Shalaby M, Embaby AM, Saeed H, Agwa MM, Hussein A. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights. Sci Rep 2020;10:14706. [PMID: 32895397 DOI: 10.1038/s41598-020-71157-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
10 Puglisi F, Bisagni G, Ciccarese M, Fontanella C, Gamucci T, Leo L, Molino A, Silva RR, Marchetti P. A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. Future Oncol 2016;12:2589-602. [PMID: 27443691 DOI: 10.2217/fon-2016-0295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Gan S, Dai H, Li R, Liu W, Ye R, Ha Y, Di X, Hu W, Zhang Z, Sun Y. Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis. Gland Surg 2020;9:661-75. [PMID: 32775256 DOI: 10.21037/gs.2020.03.40] [Reference Citation Analysis]
12 Córdova-Delgado M, Fuentes-Retamal S, Palominos C, López-Torres C, Guzmán-Rivera D, Ramírez-Rodríguez O, Araya-Maturana R, Urra FA. FRI-1 Is an Anti-Cancer Isoquinolinequinone That Inhibits the Mitochondrial Bioenergetics and Blocks Metabolic Shifts by Redox Disruption in Breast Cancer Cells. Antioxidants (Basel) 2021;10:1618. [PMID: 34679752 DOI: 10.3390/antiox10101618] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yang F, Aubele M, Walch A, Gross E, Napieralski R, Zhao S, Ahmed N, Kiechle M, Reuning U, Dorn J, Sweep F, Magdolen V, Schmitt M. Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biological Chemistry 2017;398:1151-64. [DOI: 10.1515/hsz-2017-0122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
14 Kontomanolis EN, Kalagasidou S, Pouliliou S, Anthoulaki X, Georgiou N, Papamanolis V, Fasoulakis ZN. The Notch Pathway in Breast Cancer Progression. ScientificWorldJournal 2018;2018:2415489. [PMID: 30111989 DOI: 10.1155/2018/2415489] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
15 Pizato N, Kiffer LFMV, Luzete BC, Assumpção JAF, Correa LH, Melo HAB, Sant'Ana LP, Ito MK, Magalhães KG. Omega 3-DHA and Delta-Tocotrienol Modulate Lipid Droplet Biogenesis and Lipophagy in Breast Cancer Cells: the Impact in Cancer Aggressiveness. Nutrients 2019;11:E1199. [PMID: 31141912 DOI: 10.3390/nu11061199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget 2016;7:53350-61. [PMID: 27462789 DOI: 10.18632/oncotarget.10804] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
17 Zhao H, Li D, Zhang B, Qi Y, Diao Y, Zhen Y, Shu X. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. Molecules 2017;22:E2277. [PMID: 29261144 DOI: 10.3390/molecules22122277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
18 Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes. Med Sci Monit 2017;23:4657-64. [PMID: 28957036 DOI: 10.12659/msm.905300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget 2016;7:42859-72. [PMID: 27374095 DOI: 10.18632/oncotarget.10230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Urra FA, Muñoz F, Córdova-Delgado M, Ramírez MP, Peña-Ahumada B, Rios M, Cruz P, Ahumada-Castro U, Bustos G, Silva-Pavez E, Pulgar R, Morales D, Varela D, Millas-Vargas JP, Retamal E, Ramírez-Rodríguez O, Pessoa-Mahana H, Pavani M, Ferreira J, Cárdenas C, Araya-Maturana R. FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway. Sci Rep 2018;8:13190. [PMID: 30181620 DOI: 10.1038/s41598-018-31367-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
21 De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner CJ, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA. DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. Cancer Biol Ther 2017;18:439-49. [PMID: 28475402 DOI: 10.1080/15384047.2017.1323590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
22 Kourti M, Westwell A, Jiang W, Cai J. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget 2019;10:1132-48. [PMID: 30800223 DOI: 10.18632/oncotarget.26638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Gromova I, Espinoza JA, Grauslund M, Santoni-Rugiu E, Møller Talman ML, van Oostrum J, Moreira JMA. Functional Proteomic Profiling of Triple-Negative Breast Cancer. Cells 2021;10:2768. [PMID: 34685748 DOI: 10.3390/cells10102768] [Reference Citation Analysis]
24 Kourti M, Cai J, Jiang W, Westwell AD. Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. Med Chem 2021;17:40-59. [PMID: 31808392 DOI: 10.2174/1573406415666191206102452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhao K, Yao Y, Luo X, Lin B, Huang Y, Zhou Y, Li Z, Guo Q, Lu N. LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis 2018;39:588-600. [PMID: 29390073 DOI: 10.1093/carcin/bgy007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
26 De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. Oncotarget 2016;7:43124-49. [PMID: 27281609 DOI: 10.18632/oncotarget.8988] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
27 Wright HJ, Police AM, Razorenova OV. Targeting CDCP1 dimerization in triple-negative breast cancer. Cell Cycle. 2016;15:2385-2386. [PMID: 27362899 DOI: 10.1080/15384101.2016.1204849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Jiagge E, Jibril AS, Davis M, Murga-Zamalloa C, Kleer CG, Gyan K, Divine G, Hoenerhoff M, Bensenhave J, Awuah B, Oppong J, Adjei E, Salem B, Toy K, Merajver S, Wicha M, Newman L. Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. J Glob Oncol 2018;4:1-8. [PMID: 30307804 DOI: 10.1200/JGO.18.00056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med 2017;6:547-54. [PMID: 28135048 DOI: 10.1002/cam4.1004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Res 2020;22:48. [PMID: 32414394 DOI: 10.1186/s13058-020-01280-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Al-othman N, Hammad H, Ahram M. Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells. Gene 2018;675:128-35. [DOI: 10.1016/j.gene.2018.06.094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
32 Zhu A, Yuan P, Du F, Hong R, Ding X, Shi X, Fan Y, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer. Oncotarget 2016;7:76628-34. [PMID: 27421134 DOI: 10.18632/oncotarget.10532] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
33 Xu J, Sun T, Guo X, Wang Y, Jing M. Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer. Oncol Lett 2018;15:2855-62. [PMID: 29456719 DOI: 10.3892/ol.2017.7637] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
34 Kanumuri R, Saravanan R, Pavithra V, Sundaram S, Rayala SK, Venkatraman G. Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers. Gene 2020;760:144991. [PMID: 32717309 DOI: 10.1016/j.gene.2020.144991] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]